BioMarin's Palynziq Gets FDA Approval For Phenylketonuria
Zacks Investment Research | May 24, 2018 10:57PM ET
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the FDA has approved its enzyme therapy, Palynziq (pegvaliase). The therapy will lower blood phenylalanine (Phe) levels in adult phenylketonuria (“PKU”) patients with uncontrolled blood Phe levels with existing treatment options.
The approval comes on the back of encouraging data from a phase III study – PRISM-2 – which showed that the drug significantly and substantially reduced blood Phe level compared to placebo.
Palynziq is the first enzyme therapy approved for the treatment of PKU in the United States. The drug will complement sales of Kuvan, also approved for PKU, but has lost exclusivity in the country. The company plans to launch the drug in June this year through a restricted program under a Risk Evaluation and Mitigation Strategy (“REMS”) called Palynziq REMS
An application in the EU is expected to be filed by end of the year.
Shares of the company were up 3.1% in after-hours trading following the announcement. BioMarin’s shares have lost 1% so far this year, which compares favorably with a decrease of 9.8% registered by the industry .
PKU is a rare genetic enzyme deficiency disorder that manifests at birth and if left untreated causes high levels of Phe, which leads to a variety of cumulative toxic effects on the brain. According to information provided by the company, approximately 50,000 individuals in the developed countries are diagnosed with PKU.
We note that Kuvan registered sales of $99.1 million in the first quarter of 2018, a 6.8% rise from the year-ago period. We expect Palynziq to strengthen BioMarin’s commercial leadership for the treatment of PKU, which can drive the company's revenues going forward.
BioMarin also has two late-stage candidates in its pipeline, valoctocogene roxaparvovec for Hemophilia A and vosoritide for Achondroplasia.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.